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Abstract
Aims: European Society of Cardiology/European Atherosclerosis Society 2019 guidelines recommend more aggressive
lipid targets in high- and very high-risk patients and the addition of adjuvant treatments to statins in uncontrolled patients.
We aimed to assess (a) achievement of prior and new European Society of Cardiology/European Atherosclerosis Society
lipid targets and (b) lipid-lowering therapy prescribing in a nationwide cohort of very high-risk patients.
Methods: We conducted a retrospective observational population study using linked health data in patients undergoing
percutaneous coronary intervention (2012–2017). Follow-up was for one-year post-discharge.
Results: Altogether, 10,071 patients had a documented LDL-C level, of whom 48% had low-density lipoprotein cho-
lesterol (LDL-C)<1.8mmol/l (2016 target) and (23%) <1.4mmol/l (2019 target). Five thousand three hundred and forty
patients had non-high-density lipoprotein cholesterol (non-HDL-C) documented with 57% <2.6mmol/l (2016) and 37%
<2.2mmol/l (2019). In patients with recurrent vascular events, fewer than 6% of the patients achieved the 2019 LDL-C
target of <1.0mmol/l. A total of 10,592 patients had triglyceride (TG) levels documented, of whom 14% were
2.3mmol/l and 41% 1.5mmol/l (2019). High-intensity statins were prescribed in 56.4% of the cohort, only 3%
were prescribed ezetimibe, fibrates or prescription-grade N-3 fatty acids. Prescribing of these agents was lower amongst
patients above target LDL-C, non-HDL-C and triglyceride levels. Females were more likely to have LDL-C, non-HDL-C
and triglyceride levels above target.
Conclusion: There was a low rate of achievement of the new European Society of Cardiology/European
Atherosclerosis Society lipid targets in this large post-percutaneous coronary intervention population and relatively
low rates of intensive lipid-lowering therapy prescribing in those with uncontrolled lipids. There is considerable potential
to optimise lipid-lowering therapy further through statin intensification and appropriate use of novel lipid-lowering
therapy, especially in women.
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Introduction
The European Society of Cardiology (ESC)/European
Atherosclerosis Society (EAS) 2019 guidelines for man-
agement of dyslipidaemia recommend a low-density
lipoprotein cholesterol (LDL-C) reduction of 50%
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from baseline and a LDL-C goal of <1.4mmol/
l (<55mg/dl) in very high cardiovascular disease risk
patients (reduced from <1.8mmol/l (70 g/dl) in the
2016 guidelines) and <1.0mmol/l (<40mg/dl) in
patients with recurrent atherosclerotic cardiovascular
events within the previous 2 years.1,2 These guidelines
recommend the addition of ezetimibe to statin therapy
and proprotein convertase subtilisin/kexin type 9 inhib-
itors in patients who are not at goal despite taking
maximally tolerated statin dose ezetimibe. There is
also an emphasis on the importance of considering
non-high-density lipoprotein cholesterol (non-HDL-
C) levels as secondary treatment targets, especially in
those individuals with elevated triglycerides (TGs).
Furthermore, in patients at high risk (or greater) with
TGs between 1.5–5.6mmol/l despite statin therapy,
N-3 fatty acids (N-3) should be considered.
It is unknown what proportions of patients at very
high CVD risk achieve, or do not achieve, these recom-
mended levels of LDL-C (non-HDL-C) and/or TGs;
and how these respective patient groups are treated.
A better understanding of these relationships will char-
acterise not only the therapeutic gap, but also the
potential opportunity to optimise CVD risk manage-
ment at an individual and population level. The objec-
tives of this study were to document (a) lipid-lowering
treatment and (b) achievement of prior and current
ESC/EAS lipid targets in a contemporary national
cohort of patients post-percutaneous coronary inter-
vention (PCI) population.
Method
We undertook a retrospective observational cohort
study using linked anonymised electronic health
record (EHR) data for patients undergoing PCI in
Wales, UK between January 2012–December 2017.
Access to data and linkage was performed using the
Secure Anonymised Information Linkage (SAIL) data-
bank.3,4 Study subjects included those 18 years of
age, with 90 days of follow-up. An index date was
assigned to the date of the first PCI during the study
period for each patient with follow-up for 1 year.
Lipid levels and prescriptions for lipid-modifying
therapy
The time to the first lipid profile and the lowest LDL-C,
non-HDL-C and TG level between 28–365 days post-
discharge was documented. Prescriptions were identi-
fied during follow-up for lipid-lowering therapy (LLT)
including statins, ezetimibe, fibrates and prescription-
grade N-3.
LLT prescribed in the 90 days immediately post-
discharge and within 90 days prior to the lowest
LDL-C and non-HDL-C were classified as high-
intensity statin (HI-statin; atorvastatin 40mg/d and
rosuvastatin 20mg/d), non-high-intensity (NI-statin;
any other statin prescription), combination of ezeti-
mibe and/or fibrate with either HI- or NI-statin
(combination statin) and other treatments including
ezetimibe and/or fibrate (other treatment) without a
co-prescription of statin, or no treatment.
LLT prescribed within the 90 days prior to the
lowest TG level were classified as statin (either HI- or
NI-statin); combination fibrate and/or N-3 with statin
(combination statin), fibrate and/or N-3 (other), or no
treatment.
We identified the number (and proportion) of patients
achieving (a) LDL-C< or: 1.4 and 1.8mmol/l; (b) non-
HDL-C< or : 2.2 and 2.6mmol/l (< or : 65 and
100mg/dl); (c) TG< or : 1.5 and 2.3mmol/l (135 and
200mg/dl) and their respective LLT regimen.
We also evaluated the number (and proportion) of
patients achieving LDL-C< or 1.0mmol/l and non-
HDL-C< or 1.8mmol/l and their respective LLT reg-
imens where the index PCI was a recurrent event within
2 years of a prior event.
Statistical analysis
Baseline variables are presented as mean (standard
deviation (SD)) for continuous and frequency (percent-
age) for categorical variables. Comparisons between
groups with and without lipid profiles documented
during follow-up were performed using two-sample
t-test and v2 as appropriate. Multivariable binary
logistic regression modelling was conducted to identify
variables independently associated with the absence
of a recorded lipid profile and achievement of
lipid targets.
Model selection for all analyses was conducted using
forward stepwise approach in SPSS (v22.0).
Results
Altogether, 15,203 patients met the study inclusion cri-
teria: 14,577 patient years of follow-up with mean
follow-up 349 47 days (Table 1 and Supplementary
Material Figure 1). Of the patients, 11,048 (72.7%) had
a lipid profile documented within the study period,
of whom 1154 (10.4%) had their first lipid profile
within 28 days of discharge (Supplementary Material
Figure 2). Overall, 8573 (56.4%) of patients were pre-
scribed HI-statins with the prescribing rate of these
agents considerably higher amongst those presenting
with acute coronary syndrome (ACS) as index event
(7269 (68.5%) vs 1304 (28.4%), p< 0.001). Patients
with diabetes mellitus who were prescribed LLT were
also more likely to have a lipid profile checked in
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the year post-discharge (Supplementary Material Table
1). Female sex, chronic kidney disease (CKD) stage 4þ,
dementia, ischaemic stroke, atrial fibrillation (AF) and
peripheral vascular disease (PVD) were independently
less likely to have lipid levels documented.
LDL-C levels
Of the 11,048 with any lipid profile, 10,071 patients
had an LDL-C documented between 28 days and
1 year (mean lowest LDL-C¼ 1.90mmol/l, SD¼ 0.79)
(Figure 1(a)). Of these, 4812 (47.8%) had achieved
LDL-C levels below the 2016 EAS/ESC target of
1.8mmol/l, but only 2353 (23.4%) were below the
2019 target of 1.4mmol/l.
A total of 1020 (6.7%) of patients had experienced
an atherosclerotic event within 2 years prior to the
index PCI of whom 627 had documented LDL-C
during the study period. Of these, only 33 (5.3%)
had LDL-C levels below the 2019 target of
1.0mmol/l (Figure 1(c)).
Considering patients with documented LDL-C
levels greater than 1.8 and 1.4mmol/, 2437 (46%)
and 4082 (53%) respectively were prescribed
HI-statins; only 117 (2.2%) and 146 (1.9%) respective-
ly were prescribed a combination of ezetimibe and/or
fibrate plus a statin, with 103 (2.0%) and 109 (1.4%)
prescribed ezetimibe and/or fibrate without a statin
(Figure 2).
Of the 594 of patients with recurrent events within
2 years and LDL-C 1.0mmol, 312 (52.5%) were pre-
scribed HI-statins; 214 (36.0%) were prescribed
standard-intensity statins, 19 (3.1%) were prescribed
ezetimibe and/or a fibrate in addition to a statin, 12
(2.0%) were prescribed either ezetimibe and/or fibrate
without a statin and 37 (6.2%) patients had no LLT
prescription.
Table 1. Cohort characteristic and comparison between those with and without a documented lipid profile in the first-year post-
discharge post-percutaneous coronary intervention (PCI).
Total cohort
n¼ 15,203
With lipid profile
n¼ 11,048
Without lipid profile
n¼ 4155 p Valuea
Percentage of total cohort 100% 72.7% 27.3%
Mean age (SD) 64.9 (11.9) 64.6 (11.4) 66.6 (13.0) <0.001
Male n (%) 10,933 (71.9) 8077 (73.1) 2856 (68.7) <0.001
Past medical history, n (%)
Hypertension 6331 (41.6) 4581 (41.5) 1750 (42.1) 0.46
Ischaemic heart disease 4029 (26.5) 2934 (26.6) 1095(26.4) 0.80
Previous MI 2489 (16.4) 1809 (16.4) 680 (16.4) 0.99
Previous revascularisation 1414 (9.3) 1013 (9.2) 401 (9.7) 0.36
Diabetes 3516 (23.1) 2769 (25.1) 747 (18.0) <0.001
CKD stage 4þ 182 (1.2) 96 (0.9) 86 (2.1) <0.001
Liver disease 182 (1.2) 131 (1.2) 51 (1.2) 0.83
Dementia 91 (0.6) 47 (0.4) 44 (1.1) <0.001
Heart failure 2203 (14.5) 1583 (14.3) 620 (14.9) 0.35
Ischaemic stroke 1011 (6.7) 690 (6.2) 321 (7.7) 0.001
Peripheral vascular disease 939 (6.2) 626 (5.7) 313 (7.5) 0.001
Atrial fibrillation 1634 (10.7) 1105 (10.0) 529 (12.7) <0.001
ACS during index admission 10,617 (69.8) 7978 (72.2) 2639 (63.5) <0.001
Recurrent cardiac atherosclerotic event
or non-embolic ischaemic
stroke within two years
1020 (6.7) 715 (8.0) 305 (8.6) 0.26
Stroke with two years 347 (2.3) 235 (2.6) 112 (3.2) 0.10
MI within two years 682 (4.5) 480 (5.4) 202 (5.7) 0.46
Cardiac revascularisation within two years 73 (0.5) 54 (0.6) 19 (0.6) 0.63
LLT prescribed within 90 days post-discharge <0.001
No lipid-lowering therapy 993 (6.5) 379 (3.4) 614 (14.8)
High statin 8573 (56.4) 6399 (57.9) 2174 (52.3)
Non-high-intensity statin 5179 (34.1) 3914 (35.4) 1265 (30.4)
Statin and otherb 311 (2.0) 242 (2.2) 69 (1.7)
Other LLT 147 (1.0) 114 (1.0) 33 (0.8)
ACS: acute coronary syndrome; CKD: chronic kidney disease; LLT: lipid-lowering therapy; MI: myocardial infarction; SD: standard deviation.
Other LLT indicates ezetimibe and/or fibrate.
aValue of p for comparison between those with and without a lipid profile.
bOther LLT includes prescriptions for ezetimibe and/or fibrate.
Harris et al. 3
Characteristics independently associated with LDL-C
1.4mmol/l included female sex and PVD. Diabetes
mellitus, increasing age and the presence of an ACS
during the index admission were independently associ-
ated with achieving the 2019 target LDL-C <1.4mmol/l
(Supplementary Material Table 2).
Non-HDL-C levels
Non-HDL-C levels were documented in 5340 patients
(mean lowest non-HDL-C¼ 2.6mmol/l, SD¼ 0.97) of
whom 2286 (42.8%) had a non-HDL-C 2.6mmol/l
and 3366 (63.0%) 2.2mmol/l (Figure 1(b)).
Amongst those with recurrent atherosclerotic events,
314 patient had non-HDL-C results documented, of
whom only 40 (12.7%) were below the threshold of
1.8mmol/l (Figure 1(d)).
The LLT regimens in those achieving and not
achieving target non-HDL-C levels were similarly dis-
tributed to those observed in patients at and not at
LDL-C targets (Supplementary Material Figure 3).
Characteristics independently associated with non-
HDL-C >2.2mmol/l included female sex, hypertension
and PVD (Supplementary Material Table 3). ACS
during the index admission, increasing age and LLT,
but not diabetes independently predicted non-HDL-C
<2.2mmol/l.
TG levels
A total of 10,592 patients had TG levels recorded
between 28 days and 1 year (mean lowest
TG¼ 1.54mmol/l, SD¼ 1.01), of whom 1524 (14.4%)
had TG 2.3mmol/l and 4314 (40.7%) had TG
1.5mmol/l (Figure 3).
Of those patients with TG 2.3mmol/l and 1.5,
1313 (86.2%) and 3847 (89.2%) were prescribed statins
respectively, 62 (4.1%) and 122 (2.0%) prescribed
fibrates and/or N-3 and 133 (8.7%) and 312 (7.2%)
were not prescribed any LLT (Figure 4).
In a multivariable analysis, variables independently
associated with TG>1.5mmol/l included female sex,
hypertension, CKD stage 4þ, ischaemic stroke, PVD
and diabetes mellitus.
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Figure 1. (a) Lowest low-density lipoprotein cholesterol (LDL-C) recorded between 28–365 days in 10,071 patients; (b) lowest
non–high-density lipoprotein cholesterol (non-HDL-C) recorded between 28–365 days in 5340 patients; (c) lowest LDL-C recorded
between 28–365 days in 627 patients with recurrent events; (d) lowest non-HDL-C recorded in 314 patients with recurrent events.
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Discussion
This is the first real-world study examining the pre-
scribing of LLT and achieved lipid levels against the
recently published ESC/EAS guideline targets in a
national cohort of post-PCI patients. This analysis
was conducted in order to examine the potential impli-
cations for changes in management strategy at a system
level in this very-high-risk population.
Notably, just under half (47.8%) of these very-
high-risk patients achieved LDL-C below the 2016
ESC/EAS target of 1.8mmol/l in the year post-PCI,
but fewer than a quarter (23.4%) were below the new
2019 target of 1.4mmol/l. Furthermore, fewer than 6%
of patients undergoing PCI within 2 years of a prior
admission for an ACS, non-embolic ischaemic stroke
or transient ischaemic attack (TIA) achieved the new
target of below 1.0mmol/l.
We also found that over 40% of patients had TG
1.5mmol/l, the newly introduced recommendation
for consideration of a high-dose N-3 prescription.
In keeping with our findings, a recent Canadian real-
world study has found that approximately 25% of
patients with atherosclerotic cardiovascular disease
had moderately elevated TG with controlled LDL-C,
identifying an increased event rate in these patients
compared to those with TG <1.0mmol/l.5
Prescribing of HI-statins was considerably lower
amongst patients with LDL-C levels above target.
Whilst it is possible that a proportion of these patients
were intolerant of HI-statins, it is more likely that a
greater proportion of patients prescribed NI-statins
with uncontrolled LDL-C, would be tolerant of
HI-statins, acknowledging prior reported levels of
statin intolerance in just 10–20% of statin-treated
patients.6–8 Furthermore, (co)prescribing of other
LLTs, such as ezetimibe or fibrate, was also low.
Similarly, amongst those patients with recorded TG
levels 2.3mmol/l and 1.5mmol/l, the prescribing of
fibrate or N-3s was also low, with fewer than 3% of
<1.8mmol/L ≥1.8 mmol/L
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Figure 2. Prescribed lipid-lowering therapy in patients at or above (a) 2019 and (b) 2016 European Society of Cardiology/European
Atherosclerosis Society (ESC/EAS) guideline low-density lipoprotein cholesterol (LDL-C) targets.
*Other treatment indicates prescription for ezetimibe or fibrates; statin and other indicates prescription for either high-intensity or
standard-intensity statin plus either ezetimibe or fibrate.
ϮGovernance restrictions within Secure Anonymised Information Linkage (SAIL) prohibit the reporting of numbers <5. Due to the
low number of patients prescribed ‘other’ lipid-lowering treatment with a LDL-C<1.4 we have grouped these patients with no
treatment.
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patients prescribed these treatments with or without
statins. However, these therapies are not currently
endorsed by the UK National Institute for Health
and Care Excellence (NICE).9
Although HI-statin prescription is recommended by
NICE, only 56.4% of the patients in this study were
receiving this treatment. Nevertheless, our observed
HI-statin prescribing rate was considerably higher
than documented in previous post-myocardial infarc-
tion studies, which have reported HI-statin therapy in
only 4–31% of patients.6,10,11 However, these observa-
tions were in different healthcare systems,6,11 and in
historical populations,6 rather than a contemporary
UK, post-PCI population.
To allow assessment of response to treatment and
consideration that LDL-C levels tend to fall transiently
after an ACS, we only analysed lipid profiles recorded
beyond 28 days. For patients with 1 result we identi-
fied the lowest lipid levels recorded between 28–365
days and documented the LLT prescription in the
preceding six-month period. Thus, our results do not
represent longer-term lipid management and control
beyond 1 year. However, it is well recognised that
LLT prescribing, treatment concordance and lipid con-
trol decrease progressively over time.12,13
Just under three-quarters (73.1%) of our cohort had
a lipid profile recorded during the first-year post-dis-
charge. Females and those with a history of CKD stage
4þ, ischaemic stroke, AF and/or PVD (clinical
<1.5 mmol/L ≥1.5 mmol/L
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Figure 4. Prescribed lipid-lowering therapy according to triglyceride levels.
*Other treatment indicates either fibrate or N-3 fatty acid.
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Figure 3. Lowest triglyceride recorded between 28–365 days in
10,592 patients.
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characteristics associated with worse outcomes in cor-
onary patients) were not only less likely to have lipid
levels documented, but also to have uncontrolled lipids.
Although our findings provide further evidence of
gender disparity in the management of CVD risk,
they do highlight a specific, evidence-based opportunity
to close this gap.14
Notably patients with an ACS during the index
admission were almost 2.5 times more likely to be pre-
scribed HI-statins than those undergoing PCI for stable
disease and more likely to have lipids checked within
the first year. These observations are possibly due to
the differences in clinical pathways between ACS
patients and those undergoing PCI for stable coronary
artery disease who are less likely to have changes made
to longer-term CVD prevention regimens during an
elective admission.
The 2016 non-HDL-C and LDL-C targets were
achieved in 57% and 48% of patients, whereas the
2019 respective targets where achieved in only 37% and
23% of patients, with a similar clinical picture to that
seen for LDL-C treatment and control. Importantly,
whilst diabetic patients were more likely to achieve
LDL-C targets this was not the case for non-HDL-C
targets, emphasising the importance of addressing this
measure in these very-high-risk individuals.
Two recent registry studies looked at the effectiveness
of LDL-C control in populations with coronary artery
disease (CAD).15,16 In both of these registries approxi-
mately 42% of ACS patients had LDL-C levels below
the 2016 ESC/EAS target of <1.8mmol/l, but only 28%
of those with stable CAD achieved this.
Both of these studies emphasise the difficulty faced
in achieving adequate LDL-C control across high-risk
populations, even considering the less stringent 2016
targets. These registry findings are consistent with
ours which also reflects the challenges in achieving
the even more stringent 2019 targets. It is likely that
increased use of novel therapies will be required, where
appropriate, in order to close this therapeutic gap.
Strengths and limitations
By identifying important gaps in the achievement of
ESC/EAS guideline target lipid levels, this study dem-
onstrates considerable potential to improve secondary
prevention of CVD through optimisation of evidence-
based LLT. Although these data reflect practice prior
to the publication of the 2019 guidelines, this is a
recent, representative cohort of very-high-risk patients
who would now qualify for more aggressive LDL-C,
non-HDL-C and TG targets according to the new
guidelines.
There are a number of potential limitations to this
study. While we identified the prescribing of LLT, we
were not able to identify the quantity of medication
prescribed, whether it was dispensed or if the patient
complied with therapy. This study makes no assump-
tions on medication compliance, which is often low in
chronic conditions, particularly with statins.17,18
Therefore, the prescribing of LLT reported in this
study likely describes a best-case management scenario.
We did not identify any patients who were pre-
scribed PCSK9 inhibitors in our dataset. These agents
were only approved for use within the UK National
Health Service (NHS) in June 2016.19,20 Although the
prescribing of these treatments is mainly provided
though specialist hospital outpatient clinics, for which
data was not available for this study, the uptake of
PCSK9 inhibitors within Wales has been very low.
Therefore, it is unlikely that the absence of the pre-
scribing data for these treatments would have signifi-
cantly influenced our results.
It was not possible to explore further why over a
quarter of our patients did not have a lipid profile
documented. It is unlikely that this was due to
‘loss to follow-up’ as we only included patients with
90 days follow-up (mean follow-up¼ 349 days),
allowing sufficient time to record lipid profiles post-
PCI. Patients without documented lipid levels typically
had higher risk characteristics, but we cannot deter-
mine whether this difference is explained by confound-
ing factors or a risk-treatment paradox.
It is possible that some patients had lipid profiles
documented post-discharge within secondary care
pathology datasets that were not available for this
study. However, longer-term risk factor management
is undertaken in primary care for the vast majority of
patients in Wales in both the primary and secondary
prevention settings.
Lipid profiles recorded during the index admission
were also not available for this study. While we cate-
gorised patients at or above target levels, we were not
able to calculate the percentage LDL-C reduction from
baseline. It is therefore likely that an even greater
number of patients would not have achieved a 50%
reduction in LDL-C target levels.
In this study, 6.7% of patients were classified as
having recurrent atherosclerotic events, including a
previous hospital admission for an ACS, coronary
revascularisation, non-embolic stroke or TIA within
2 years before the index PCI. Due to ambiguity of clin-
ical coding of PVD within the secondary care hospital
datasets, we were unable to accurately detect acute
peripheral vascular events and therefore these were
not included. We noted that a far greater number
of our patient cohort had experienced prior clinical
atherosclerotic events, but over 2 years before the
index PCI.
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It was beyond the scope of this study to evaluate the
relationships between early post-PCI lipid levels, LLT
strategy and clinical outcomes in the first year
post-PCI. The purpose of this short report was to char-
acterise the nature of LLT and achievement of lipid
targets according to contemporary ESC/EAS2 guid-
ance at the time of PCI. This identifies the potential
for further optimisation of lipid management in this
very-high-risk cohort with reference to the new guide-
line targets and recommended treatments. Therefore,
future prospective evaluation will be required to eval-
uate the how changes in lipid management impact on
lipid levels and clinical outcomes at a population level.
A last, but important, consideration is that the data
for this study were obtained from patients treated in
the Welsh NHS, where the cost of healthcare, including
prescription drugs, is entirely free at the point of deliv-
ery. This mitigates against potential barriers of afford-
ability of follow-up consultation, lipid monitoring
and medication purchasing. These would be important
considerations when comparing the findings of our
study to other healthcare systems, where greater dis-
crepancies in quality of care might be expected in
more economically disadvantaged individuals and
populations.21
We have identified a relatively low rate of prescrib-
ing of HI-statins additional evidence-based LLT
agents in a large post-PCI patient population, as well
as a relatively low proportion of these patients achiev-
ing the new EAS/ESC lipid targets. Our data suggest
that there is considerable potential to optimise LLT
through statin intensification and appropriate use of
novel LLT, which would be expected to improve clin-
ical outcomes at both an individual and population
level. However, the budgetary impact of novel manage-
ment strategies and thus potential value to healthcare
providers and funders will need to be carefully planned
and evaluated.
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